Abstract
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors
Journal of clinical oncology, Vol.37(15_suppl), pp.4111-4111
05/20/2019
DOI: 10.1200/JCO.2019.37.15_suppl.4111
Abstract
4111
Background: The primary statistical analysis for the NETTER-1 trial showed a clinically and statistically significant PFS benefit with
177
Lu-DOTATATE vs. high-dose octreotide.
177
Lu-DOTATATE treatment was also correlated with a significant delay in time to deterioration in HRQoL. In addition to HRQoL questionnaires, patients were asked to record presence or absence of a range of symptoms in a daily diary. Methods: A Mixed Model Repeated Measures (MMRM) was used to analyze the change, compared to baseline, of the occurrence of abdominal Pain, diarrhea and cutaneous flushing as these symptoms were regarded as the most relevant to judge the overall disease status. For each visit (week = 0, 4, 8, etc.) the number of days with symptoms during the previous period was calculated. At baseline, the number of days with symptoms was counted over the previous 6 weeks, whereas the time frame between visits lasted 4 weeks. Results: The estimated number of days with symptoms declined significantly more in the
177
Lu-dotatate arm compared to the octreotide arm. The difference in change and the confidence intervals for the symptoms abdominal pain, diarrhea and flushing of skin are, respectively: -3.11 [-4.88; -1.34], -3.11 [-5.04; -1.18] and -1.98 [-3.88; -0.08]. Conclusions: Analysis of symptom diaries confirms that
177
Lu-Dotatate can palliate clinically relevant symptoms when compared to high-dose octreotide.
Details
- Title: Subtitle
- Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors
- Creators
- Jonathan R. Strosberg - Moffitt Cancer CenterEdward M. Wolin - University of KentuckyBeth A. Chasen - The University of Texas MD Anderson Cancer CenterMatthew H. Kulke - Boston Medical CenterDavid L Bushnell - Veterans Administration Medical Center, Iowa City, IAMartyn Caplin - The Royal Free HospitalRichard P. Baum - Zentralklinik, Bad Berska, Bad Berska, GermanyTimothy J. Hobday - Mayo ClinicAndrew Eugene Hendifar - Cedars-Sinai Medical CenterPaola Santoro - Advanced Accelerator Applications, Geneva, SwitzerlandPer Broberg - Advanced Accelerator Applications, Geneva, SwitzerlandArnaud Demange - Advanced Accelerator Applications, Geneva, SwitzerlandKjell E. Oberg - Uppsala University HospitalPhilippe B. Ruszniewski - Beaujon HospitalLaura Ravasi - Advanced Accelerator Applications, Geneva, SwitzerlandEric Krenning - Erasmus MC
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.37(15_suppl), pp.4111-4111
- DOI
- 10.1200/JCO.2019.37.15_suppl.4111
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2019
- Academic Unit
- Radiology
- Record Identifier
- 9984320014502771
Metrics
8 Record Views